Table 1.
Baseline patient demographics and disease histories
| Age, years | |
| Median | 63.8 |
| Range | 49–73 |
| Sex | |
| Male | 10 |
| Female | 5 |
| ECOG performance status | |
| 0 | 6 |
| 1 | 9 |
| Disease subtype at diagnosis | |
| Acute | 3 |
| Lymphoma | 10 |
| Unfavorable chronic | 2 |
| Prior treatment | |
| Number of prior chemotherapy regimens | |
| 1 | 5 |
| 2 | 7 |
| 3 | 1 |
| 4 | 1 |
| 7 | 1 |
| Prior chemotherapy regimens | |
| CHOP, CHOP-like | 9 |
| VCAP-AMP-VECP | 6 |
| Multi-agents other than above | 5 |
| VP-16 | 6 |
| VP-16 + sobuzoxane | 3 |
| Mogamulizumab | 3 |
| Sobuzoxane | 1 |
| Lenalidomide | 1 |
| Radiation | 2 |
| Allogeneic stem cell transplantation | 1 |
CHOP, combination chemotherapy consisting of vincristine (VCR), cyclophosphamide (CPM), doxorubicin (DOX), and prednisolone (PSL). VCAM-AMP-VECP, sequential combination chemotherapy consisting of VCAP (VCR, CPM, DOX, and PSL), AMP (DOX, ranimustine, and PSL), and VECP (vindesine, etoposide, carboplatin, and PSL).